Sandoz, the global leader in generic and biosimilar medicines, today announces the launch of Hyrimoz® (adalimumab) citrate-free high concentration formulation (HCF; 100 mg/mL) in Europe. The medicine will become available to patients progressively across European markets, starting today. Hyrimoz® HCF,…
Guy’s and St Thomas’ NHS Foundation Trust’ and King’s College London will set up a new HealthTech Research Centre focussing on cardiovascular and respiratory medicine. The centre, based at St Thomas’ Hospital, will work with industry and academic partners as…
Abdi Ibrahim Pharmaceuticals, the leader in the Turkish pharmaceutical industry for 21 years, continues its unwavering commitment to investing in biotechnology. Abdi İbrahim has announced a technology transfer agreement with the Spanish biosimilar developer, which is among the world’s leading…
AstraZeneca today launches Evinova, set to be a leading provider of digital health solutions to better meet the needs of healthcare professionals, regulators and patients. With long-term backing from AstraZeneca and strategic collaborations with Parexel and Fortrea, Evinova offers globally-scaled…
AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in the US for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more biomarker alterations (PIK3CA, AKT1 or…
The University of Tsukuba and Astellas Pharma announced that they have signed a letter of confirmation regarding a strategic partnership to accelerate the digitalization of the drug discovery research field, as well as the development of the life science ecosystem…
Vertex Pharmaceuticals and CRISPR Therapeutics announced that the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional marketing authorization for CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited therapy, for the treatment of sickle cell disease (SCD) and…
Astellas Pharma and Pfizer today announced that the companies received an approval by the FDA of a supplemental New Drug Application for XTANDI® (enzalutamide), following FDA expedited development and review programs (Priority Review designation, Fast Track designation, Real-time Oncology Review),…
Investigators from the UCLA Health Jonsson Comprehensive Cancer Center have developed an artificial intelligence (AI) model based on epigenetic factors that is able to predict patient outcomes successfully across multiple cancer types. The researchers found that by examining the gene…
Bristol Myers Squibb announced that FDA approved Augtyro™ (repotrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). Administered as an oral therapy, Augtyro is a tyrosine kinase inhibitor (TKI) targeting ROS1…